The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

乳腺癌脑转移严重威胁患者生命，HER2 阳性亚型更易发生且治疗棘手。研究人员聚焦 HER2 阳性乳腺癌，探究 GRB2 与脑转移关系。结果发现 GRB2 可促肿瘤细胞增殖、转移，与 HER2 协同作用，这为治疗提供新靶点和方向。 在癌症的世界里，乳腺癌如同一个可怕的 ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

Structurally, Enhertu consists of topoisomerase I inhibitor payloads (DXd or deruxtecan) linked with a cleavable tetravalent peptide to an anti-HER2 antibody. The HER2 antibody has the same ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...